Abstract
Background: Human immunodeficiency virus type 1 (HIV-1) is one of the fastest evolving human pathogens. Understanding transmission, within-host adaptation, and evolutionary dynamics are pivotal for development of interventions and vaccines. HIV-1 infection is generally caused by one single transmitted founder virus (TFV), and TFV sequences have typically been obtained using single genome amplification (SGA). However, suboptimal sample quality can result in sequencing failures, representing non-trivial losses considering the scarcity of acute HIV-1 infection (AHI) samples. Sequencing failures may be mitigated by molecular cloning (MC), a method that can be less vulnerable to sample quality but more susceptible to PCR errors. Here, we explore the feasibility of supplementing SGA with MC data using samples from clinical and research cohorts to determine whether sequence diversity and evolutionary rate estimates are comparable between the two techniques. Methods: Participants were enrolled in an East African research cohort from the International AIDS Vaccine Initiative 2006-2011 or a clinical cohort from Sweden (1983-2011). SGA and MC sequencing were done on the HIV-1 env V1-V3 region (approximately 940 base pairs). Within-host sequence diversity was determined from maximum likelihood phylogenetic trees and evolutionary rate by Bayesian phylogenetic analysis. Highlighter and Poisson-Fitter tools, Hamming distances, and assessment of star phylogenies were used to quantify TFVs. Results: Participants with AHI (N=100, median age 30.3 years, 15% female) were included, contributing 350 samples from four longitudinal time points 10-540 days post infection. SGA succeeded on 90% of research cohort and 48% of clinical cohort samples. Comparative analysis of linked SGA and MC data from 10 samples indicated that approximately eight sequences were necessary for diversity estimates. Consistently higher sequence diversity was observed among MC relative to SGA sequences (mean±SD 0.009±0.007 and 0.006±0.006 substitutions/site, p<0.001), whereas evolutionary rates were similar between the two methods (mean±SD 0.014±0.006 vs. 0.014±0.009 substitutions/site/year, p=0.673). Five participants with visits within 45 days post infection were eligible for TFV quantification and all found to have one TFV using both MC and SGA data. Conclusion: MC data is a suitable supplement for SGA-based studies to preserve the value of precious samples for evolutionary rate but not sequence diversity analysis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded in part by the generous support of the American people through the United States Agency for International Development (USAID), the Swedish Research Council (grant # 2016-01417), the Swedish Society for Medical Research (grant # SA-2016) and the Sub-Saharan African Network for TB/HIV-1 Research Excellence (SANTHE), a DELTAS Africa Initiative (grant # DEL-15-006). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (grant # 107752/Z/15/Z) and the UK government. J.E was supported by funding from the Swedish Research Council (grant # 2020-06262). A.S.H was supported by a Training fellowship from the Wellcome Trust (209294/Z/17/Z). A.H was supported by the Canadian Institutes of Health Research (ref: 202012HIV-464257-268748); the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China (ref: 2018-I2M-2-002); and the Thrasher Research Fund (ref: 01662). The contents are the responsibility of the study authors and do not necessarily reflect the views of USAID, the NIH, the United States Government, the Swedish Research Council or the Wellcome Trust.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Kenyatta National Hospital Ethical Review Committee of University of Nairobi gave ethical approval for this work. Rwanda National Ethics Committee gave ethical approval for this work. Uganda Virus Research Institute Science and Ethics Committee gave ethical approval for this work. Uganda National Council of Science and Technology gave ethical approval for this work. University of Zambia Research Ethics Committee gave ethical approval for this work. Emory University Institutional Review Board gave ethical approval for this work. Lund University Ethical Review Board gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos